melanocortin receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Outside farms, forests cover just 43.52% of the EU's land, compared to 80% forest cover historically across Europe. There is no requirement yet to undertake any reforesting or rewilding of land, while the Land Use and Forestry Directive 2018 merely requires that member states keep accounts of land use and forestry changes based on greenhouse gas emissions, and that emissions do not exceed removals of greenhouse gases. Globally, the Timber Regulation 2010 requires that all timber traders know their supply chains and keep records for 5 years, to ensure that any illegally harvested timber is banned in the EU law, however there is not yet any ban on imports of goods (such as beef or palm oil) from countries that continue to deforest their landscape. For water resources, in nature or for drinking, the Water Framework Directive 2000 sets common standards and provides that member states should oversee water industry standards. The Drinking Water Quality Directive 2020 requires water that is "wholesome and clean", and article 4 defines this as free from micro-organisms and parasites dangerous to health, and compliant with chemical and biological standards in Annex I. The Bathing Waters Directive 2006 sets standards for quality of bathing waters, namely riviers and beaches, to be free from toxic waste or sewage. There must be adequate remedies for breaches, so in Commission v United Kingdom (1992) it was held that the UK's approach of accepting undertakings from water companies to behave better in future, instead of using enforcement orders, was inadequate to comply with EU law.
=== Visas === Seeking to reverse a policy of Bolsonaro — which, according to the current government, made the decision to "break with the pattern of Brazilian migration policy, historically grounded in the principles of reciprocity and equal treatment" — the government instructed the Itamaraty to once again require visas for entry into Brazil by citizens of Australia, Canada, the United States, and Japan, just as these countries already do when it comes to Brazilian citizens. The decision was taken after consultations with the governments of these four countries regarding the possibility of also exempting Brazilians from visas, in accordance with the principle of reciprocity; a principle that the Ministry of Foreign Affairs had already defended since 2017, when it opposed a proposal by the Ministry of Tourism to permanently remove the visa requirement for these countries. The Itamaraty's decision had also taken into account a decree issued by then president Donald Trump in January 2017, intended to complicate the granting of visas to citizens of several countries, among which Brazil was included.
Since their construction and decoration between the 4th and 8th centuries CE, the Kizil Caves have suffered numerous periods of religious vandalism and decay. Western archaeologists orchestrated the massive sampling on the best remaining works of art in the early 20th century. Aside from their colonial outlook, one of their alleged motivations was to protect these works of arts from vandalism due to Islamic iconoclasm and the depredations of treasure hunters. Most of the dismantled panels were sent to the Museum für Indische Kunst, Berlin, Germany, but many were destroyed in World War II, with only photographs or drawings remaining in the best cases. A significant number of the murals were also captured by the Soviets in Berlin, and turned up recently in the Hermitage Museum. In more recent times, the Red Guards also contributed to the destruction of the site, and last but not least, the transformation of the site for touristic purposes since 2005 has led to the disfigurement of many caves and the irretrievable loss of archaeological knowledge. Today, none of the caves can be said to have remained entirely intact, although many remain quite impressive.
Sources: en.wikipedia.org
=== Economics === In 2008, it generated the tenth-highest amount of money for a medication in the U.S. in 2008, with sales exceeding $2.4 billion. To 2020, no study has examined the socioeconomic effects of utilization of pioglitazone.
== Narcoterrorism == An unwanted by-product of Bolivia's cocaine industry was the importation of Colombian-style drug violence. In the late 1980s, Colombia's Medellín Cartel reportedly wielded considerable power in Bolivia, setting prices for coca paste and cocaine and terrorizing the drug underworld with hired assassins. Furthermore, drug barons, organized into families, had established their own fiefdoms in Cochabamba, Beni, and Santa Cruz departments, using bribes and assassinations to destroy local authority. In September 1986, three members of a Bolivian scientific team were slain in the Huanchaca National Park in Santa Cruz Department shortly after their aircraft landed beside a clandestine coca-paste factory. The murders led to the discovery of the country's largest cocaine-processing installation, as well as evidence of an extensive international drug-trafficking organization consisting mostly of Colombians and Brazilians. President Paz Estenssoro fired the Bolivian police commander and deputy commander as a result of their alleged involvement. In a related action, suspected traffickers in Santa Cruz murdered an opposition deputy who was a member of the congressional commission that investigated the Huanchaca case. In the late 1980s, there were several incidents of narcoterrorism against the United States presence, the judiciary, and antidrug agents. For example, the so-called Alejo Calatayu terrorist command claimed responsibility for a May 1987 bomb attack against the Cochabamba home of a DEA agent.
7759 University Drive 7777 University Drive 7798 Discovery Drive Anderson Building Barrett Building, home to the University of Cincinnati Cancer Center Blood Cancer Healing Center Bridgeway Pointe Clifton Physicians Office Building Dental Center East Building Elizabeth Place Florence Building Holmes Building Hoxworth Center Liberty Township Building Lindner Center of HOPE Mason Building Midtown Building Milford Building Montgomery Building North Building Proton Therapy Center Radiotherapy Ridgeway Tower Rookwood Tower Sleep Medicine Center South Building Surgical Center Timothy Freeman, MD, Center for Developmental Disabilities Trenton Building Tri-County Building University of Cincinnati Gardner Neuroscience Institute UC Medical Center UC Medical Center Emergency Department Varsity Village Imaging Center West Building West Chester Hospital West Chester Hospital Emergency Center White Oak Building Wyoming Primary Care
Sources: en.wikipedia.org
== Clinical significance == Mutations in this gene are associated with type II Stickler syndrome and with Marshall syndrome. Stickler syndrome, type II is an autosomal dominant condition caused by a mutation in the COL11A1 gene. Features of Stickler syndrome type II include: sensorineural hearing loss, facial features (flat facial profile, anteverted nares, micrognathia), cleft palate, visual disturbances (type 2 vitreous anomaly, childhood-onset myopia, glaucoma, cataracts and retinal detachment), spondyloepiphyseal dysplasia, and arthropathy.
=== Musculoskeletal === Musculoskeletal symptoms include hyperflexible joints that are unstable and prone to sprain, dislocation, subluxation, and hyperextension. As a result of frequent tissue injury, there can be an early onset of advanced osteoarthritis, chronic degenerative joint disease, swan-neck deformity of the fingers, and Boutonniere deformity of the fingers. Tendon and ligament laxity offer minuscule protection from tearing in muscles and tendons, but these problems persist. Deformities of the spine, such as scoliosis (curvature of the spine), kyphosis (a thoracic hump), tethered spinal cord syndrome, craniocervical instability (CCI), and atlantoaxial instability may also be present. Osteoporosis and osteopenia are also associated with EDS and symptomatic joint hypermobility. There can also be myalgia (muscle pain) and arthralgia (joint pain), which may be severe and disabling. Trendelenburg's sign is often seen, which means that when standing on one leg, the pelvis drops on the other side. Osgood–Schlatter disease, a painful lump on the knee, is common as well. In infants, walking can be delayed (beyond 18 months of age), and bottom-shuffling instead of crawling occurs.
== Part 1 == This 90-minute video shows how Metallica and their producer Bob Rock worked their way through making the Metallica album. It also includes the making of the video for "Enter Sandman" and also a listening party for invited fans to come and listen to the album in full. The video as well highlights tensions between Bob Rock and Metallica. The infamous exchange between Kirk Hammett and Bob Rock during the recording of "The Unforgiven" guitar solo is documented. This video also includes three of the music videos the band shot for that album:
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.